LOGIN  |  REGISTER
C4 Therapeutics
Chimerix

Clinician Use of Clover Health Assistant is Associated with Significant Improvement in the Early Identification and Management of Chronic Kidney Disease

August 01, 2023 | Last Trade: US$3.40 0.04 -1.02

FRANKLIN, Tenn., Aug. 01, 2023 (GLOBE NEWSWIRE) -- Today, Clover Health (“Clover” or “the Company”) issued an analysis titled Clover Assistant Use and Diagnosis and Progression of Chronic Kidney Disease, which examines the association between use of the company’s flagship technology product, Clover Assistant (“CA”), and earlier physician identification and management of stage three chronic kidney disease (“CKD”).

“Our findings demonstrate that use of Clover Assistant supports earlier diagnosis and management of chronic disease,” said Dr. Kumar Dharmarajan, Chief Medical Officer of Clover Assistant. “Importantly, we’re seeing that when doctors use Clover Assistant, not only is CKD diagnosed earlier in its progression, but the rate of kidney decline decelerates. While chronic deterioration of kidney function cannot be reversed, any deceleration delays CKD complications like heart attacks and strokes, and reduces health costs. We’re using technology in a scalable way to positively influence physician behavior and improve lives.”

“To reduce any potential for bias, the analysis leverages data from the same physician cohort before and after their adoption of Clover Assistant. By removing this variable, we can confidently ascertain that the disease identification models within Clover Assistant are catalysts for improved disease management,” added Peter Loscutoff, Data Science Fellow at Clover.

“Clover Assistant helps me manage my patients’ CKD earlier. I find that when using it with my Clover patients, I am ordering CKD-related tests like parathyroid hormone (PTH) sooner, which then allows me to manage the condition and its complications earlier,” said Dr. Amr Kahf of The Armor Medical Group, in Haledon, New Jersey.

The full results are available on Clover’s website: www.cloverhealth.com/clinicalcare/ckd

About Clover Health

Clover Health (Nasdaq: CLOV) is a physician enablement company committed to bringing access to great healthcare to everyone on Medicare. This includes a health equity-based focus on seniors who have historically lacked access to affordable, high-quality healthcare. Our strategy is powered by our software platform, Clover Assistant, which is designed to aggregate patient data from across the healthcare ecosystem to support clinical decision-making and improve health outcomes through the early identification and management of chronic disease. We operate two distinct lines of business: Insurance and Non-Insurance. Through our Insurance line of business, we provide PPO and HMO Medicare Advantage plans in several states, with a differentiated focus on our flagship wide-network, high-choice PPO plans. Our Non-Insurance line of business similarly aims to reduce cost-of-care while enhancing the quality of care for patients enrolled in Original Medicare.

Press Contact:
Andrew Still-Baxter
This email address is being protected from spambots. You need JavaScript enabled to view it.

Investor Relations Contact:
Ryan Schmidt
This email address is being protected from spambots. You need JavaScript enabled to view it.

Stock Quote

Featured Stock

Recursion

Recursion Pharmaceuticals is a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery. Enabling its mission is the Recursion OS, a platform built across diverse technologies that continuously expands one of the world’s largest....

CLICK TO LEARN MORE

Featured Stock

Amneal Pharmaceuticals

Amneal Pharmaceuticals is a fully-integrated essential medicines company. We make healthy possible through the development, manufacturing, and distribution of generic and specialty pharmaceuticals. The Company has a diverse portfolio of over 250 products in its Generics segment and is expanding across...

CLICK TO LEARN MORE

End of content

No more pages to load

Next page

COPYRIGHT ©2023 HEALTH STOCKS HUB